- Home
- Ibogaine as a Treatment for Parkinson’s Disease
Ibogaine as a Treatment for Parkinson’s Disease
Ibogaine as a Treatment for Parkinson’s Disease
Over 55 million people worldwide are affected by neurodegenerative diseases, such as Alzheimer’s, multiple sclerosis, and Parkinson’s, which can cause memory loss and disabilities. The spotlight on these conditions intensified after 2000, when Canadian-American actor Michael J. Fox, diagnosed with Parkinson’s 30 years ago, established the Michael J. Fox Foundation for Parkinson’s Research.
Parkinson’s disease, the second most common neurodegenerative disorder after Alzheimer’s, arises from the degeneration of dopamine-producing neurons in the mid-brain. This degeneration triggers progressive symptoms like tremors, muscle rigidity, speech impairments, and poor balance, as well as cognitive and mood disorders like dementia and depression. It affects approximately 7 to 10 million people globally. Current treatments only alleviate symptoms without reversing the disease.
In the United States alone, over 1 million people have Parkinson’s disease, a figure projected to increase by 60% within two decades. It is believed that autoimmune reactions may play a role in its pathogenesis before symptoms appear. With no cure available, treatment strategies are focused on managing symptoms and extending life quality.
Potential of Ibogaine in Slowing Parkinson’s Disease
Research indicates that although the adult brain has limited regenerative capacity, it can still produce new neurons throughout a person’s life. A specific protein, Nurr1, crucial for the development of dopamine-managing neurons, plays a significant role in this process and has been linked to Parkinson’s disease. Enhancing this protein’s function could potentially slow the progression of the disease.
A team at Columbia University is exploring whether ibogaine, primarily researched for addiction treatment, could also benefit Parkinson’s disease patients by promoting the protein glial cell-derived neurotrophic factor (GDNF). This protein supports the regeneration of dopaminergic fibers, which could improve symptoms by repairing damaged neurons. Previously, increasing GDNF levels required complex treatments like gene therapy, but ibogaine may offer a simpler, safer alternative.
Clinical Developments and Future Prospects of Ibogaine
Despite regulatory challenges, ongoing research supports the potential of ibogaine to release GDNF, potentially offering lasting psychological benefits by fostering a state of neurological adaptability. This “reset” could repair pathways damaged by addiction.
At a partner institute of Tabula Rasa’s Retreat in Mexico, a pharmaceutical version of ibogaine, CKBR-12, is under evaluation for treating Parkinson’s disease. Early clinical trials have shown promising results in improving motor and non-motor symptoms, significantly enhancing patients’ quality of life. The rapid improvements observed have led to the filing of provisional patent applications for a method that rapidly reduces Parkinson’s symptoms.
Significant improvements in movement, balance, and speech were noted, along with reductions in drooling. Notably, no psychological adverse effects were reported during the 30-day treatment period. The promising results are supported by patient-reported outcomes and video assessments.
Despite ibogaine being illegal in the U.S., it is used experimentally in countries like Canada, Mexico, and Portugal. As an experimental drug, it requires extensive clinical trials before it can be approved more broadly. Nonetheless, the unique potential of ibogaine to treat neurodegenerative diseases like Parkinson’s may draw significant research investment, providing hope where few treatments have succeeded.